文献速递肿瘤 PET/CT

FLT与FDG PET/CT在IB-IIIA期可切除非小细胞肺癌化疗早期疗效评估中的比较

A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-IIIA resectable NSCLC.
PubMed 文献 · EJNMMI Res · 2017-01-19

本研究比较基线至第一周期化疗后18F-氟胸腺嘧啶(FLT)与18F-氟脱氧葡萄糖(FDG)标准摄取值变化,以第二周期后RECIST 1.1 CT判定的应答者与非应答者为参照。9例新诊断可手术非小细胞肺癌患者接受FDG PET/CT、FLT PET/CT及CT检查。应答者FDG与FLT SULmax分别平均下降44.8%与32.0%,非应答者分别平均上升7.0%与3.4%。

要点

  • 应答者基线至第一周期后FDG与FLT SULmax分别平均下降44.8%与32.0%,非应答者分别平均上升7.0%与3.4%。
  • 第一周期后原发灶FDG SUL值应答者显著低于非应答者(P=0.016),FLT SUL值两组间无显著差异。
  • 基线至第一周期变化预测第二周期后解剖学应答的ROC曲线下面积FDG为0.94、FLT为0.78。

核心结论

  • 基线至第一周期后FDG SULmax下降百分比在解剖学应答者与非应答者间有显著差异,而同期FLT SULmax变化百分比在两组间无显著差异。

研究设计与样本

  • 9例新诊断、可手术的非小细胞肺癌(NSCLC)患者,在基线、第一周期新辅助化疗(多西他赛75 mg/m2+顺铂75 mg/m2)后及第二周期治疗后分别行FDG PET/CT、FLT PET/CT和CT检查。
  • 所有患者入组前均行活检,并在第二周期后影像检查4周内接受手术切除。
  • 按第二周期治疗后RECIST 1.1 CT将患者分为应答者与非应答者,比较基线至第一周期后FLT与FDG标准摄取值变化百分比。

主要发现

  • 基线至第一周期后,非应答者FDG与FLT的SULmax分别平均上升7.0%与3.4%。
  • 基线至第一周期后,应答者FDG与FLT的SULmax分别平均下降44.8%与32.0%。
  • 第一周期后影像中,原发灶FDG SUL值应答者显著低于非应答者(P=0.016)。
  • 第一周期后影像中,原发灶FLT SUL值在应答者与非应答者间无显著差异。
  • 用基线至第一周期后的变化预测第二周期后解剖学肿瘤应答,ROC分析示曲线下面积FDG为0.94、FLT为0.78。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this study was to compare the percentage change in 18F-fluorothymidine (FLT) standard uptake value (SUV) between baseline and after one cycle of chemotherapy in patients categorized by RECIST 1.1 computed tomography (CT) as responders or non-responders after two cycles of therapy. Change in 18F-fluorodeoxyglucose (FDG) uptake was also compared between these time points. Nine patients with newly diagnosed, operable, non-small cell lung cancer (NSCLC) were imaged with FDG positron emission tomography/CT (PET), FLT PET/CT, and CT at baseline, following one cycle of neoadjuvant therapy (75 mg/m2 docetaxel + 75 mg/m2 cisplatin), and again after the second cycle of therapy. All patients had a biopsy prior to enrollment and underwent surgical resection within 4 weeks of post-cycle 2 imaging. RESULTS: Between baseline and post-cycle 1, non-responders had mean SULmax (maximum standard uptake value adjusted for lean body mass) increases of 7.0 and 3.4% for FDG and FLT, respectively. Responders had mean decreases of 44.8 and 32.0% in FDG and FLT SULmax, respectively, between baseline and post-cycle 1 imaging. On post-cycle 1 imaging, primary tumor FDG SUL values were significantly lower in responders than in non-responders (P = 0.016). Primary tumor FLT SUL values did not differ significantly between these groups. Using the change from baseline to post-cycle 1, receiver-operating characteristic (ROC) analysis showed an area under the curve (AUC) of 0.94 for FDG and 0.78 for FLT in predicting anatomic tumor response after the second cycle of therapy. CONCLUSIONS: Fractional decrease in FDG SULmax from baseline to post-cycle 1 imaging was significantly different between anatomic responders and non-responders, while percentage changes in FLT SULmax were not significantly different between these groups over the same period of time.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Crandall JP, Tahari AK, Juergens RA, et al. A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-IIIA resectable NSCLC. EJNMMI Res. 2017. PMID: 28102506. doi:10.1186/s13550-017-0258-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。